I2O Therapeutics Inc., of Allston, Mass., raised $4 million in seed funding to further its work on oral formulations of therapies typically limited to injections, such as biologics, large molecules and peptide-based pharmaceuticals.

LONDON – Amphista Ltd. becomes the latest to join the growing band of proteolysis targeting chimera (Protac) specialists, arriving on the scene with a $7.5 million series A and what it says is a new approach to targeted protein degradation (TPD).

LONDON – A founding father of anti-angiogenesis therapy, Peter Carmeliet is turning his previous work on its head in new research which indicates that rather than destroying tumor vasculature, it should be piggy-backed as a means to recruit immune cells to a tumor.

TORONTO – That old military saw “an army marches on its stomach” might just as easily apply to transport of much needed ventilators for patients suffering from the coronavirus. Mounting systems for ground and air ambulances like the Bracket Pro Serie for Ventilators launched March 5 by Quebec City-based Technimount System Inc. are the “soldiers” carrying ventilators and other medical devices for hospital bound patients, Technimount CEO Carl Bouchard told BioWorld.

Astrotech Corp., of Austin, Texas, has a broad range, having developed mass spectrometers in agriculture and manufacturing and selling chemical analyzers for use in the airport security and other applications. Now, it is looking to help in the fight against COVID-19.

Zurich-based startup Ava Science Inc. recently issued a public call for partners and funding to further research the potential usefulness of its fertility wearable, known as Ava Bracelet, during the COVID-19 pandemic.

BOGOTA, Colombia – As the world turns its attention to COVID-19 and its impacts across the globe, in Latin America diseases like Chagas continue to keep scientists busy. In Argentina, researchers are working on an innovative solution to deal with a major threat to the region’s public health.

Nineteengale Therapeutics is a new joint venture that was launched to fill a large void. Cyclica Inc., along with its partner, Neurotheryx Canada Ltd., both of Toronto, created Nineteengale to find and develop cannabinoid-inspired drugs for bipolar disorder, anxiety and pain management.

Beta-O2 Technologies Ltd. plans to enroll its first patients in clinical trials for its second-generation bio-artificial pancreas, ßAir, in the coming months. The small, implantable titanium device has separate components that hold pancreatic cells and a rechargeable oxygen tank. Beta-O2 is based in Rosh-Haayin, Israel.

Lessons learned from development of hepatitis C therapies could be applied to the underserved hepatitis B population, potentially leading to a functional cure through a combination of optimized drugs that attack the virus from different angles. That is the mission of 2-year-old Aligos Therapeutics Inc., a South San Francisco-based startup focused on liver-related diseases.